Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 10

recruiting
3 968
countries
28
conditions
2 103

606 trials match your criteria

Early Treatment with Argipressin (Arginine Vasopressin) in Adult Intensive Care Patients with Norepinephrine-Resistant Vasoplegic Shock

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin

Comparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Study Evaluating Direct Oral Anticoagulants for Prevention of Blood Clots in Patients with Hypertrophic Cardiomyopathy and Abnormal Left Atrial Function

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rivaroxaban

Study of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Study on the Effect of Continuous Intravenous Lidocaine and Sodium Chloride on Comfort in Postoperative Critical Care Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab

Study on the Safety and Effects of DNL593 for Patients with Frontotemporal Dementia

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:DNL593

Study Comparing Tepotinib to Standard Treatment for Patients with Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib

Study comparing NVL-655 to alectinib in untreated patients with ALK-positive advanced non-small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nvl-655
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.